Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06172478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06172478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Recruiting
Start date
February 26, 2024
Completion date
October 10, 2028
Enrollment
740 (estimated)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, bladder cancer, breast cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, lung cancer, melanoma, non-small cell lung cancer (nsclc), ovarian carcinoma, pancreatic carcinoma, prostate cancer